Humana Inc. (HUM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with a 12% YoY revenue increase, a 15% rise in operating cash flow, and a 10% increase in net income. EPS also grew significantly, supported by share repurchases. The improvement in the Medical Expense Ratio suggests effective cost management. Although there were no operational or strategic updates, the financial metrics alone suggest a positive outlook. Without Q&A insights, the financials remain the primary positive driver.
Key Financial Performance
Revenue Revenue for Q1 2026 was $26.7 billion, representing a 12% increase year-over-year. This growth was driven by higher Medicare Advantage membership and improved pricing.
Operating Cash Flow Operating cash flow for the quarter was $2.1 billion, up 15% year-over-year. The increase was attributed to strong collections and efficient working capital management.
Net Income Net income for Q1 2026 was $1.2 billion, a 10% increase compared to the same period last year. This was due to improved operating performance and cost management initiatives.
Earnings Per Share (EPS) EPS for the quarter was $9.50, up from $8.60 in Q1 2025, reflecting a 10.5% increase. The rise was supported by higher net income and share repurchases.
Medical Expense Ratio (MER) The MER was 85.2%, an improvement of 0.8 percentage points year-over-year. This was due to better cost control and favorable claims experience.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Albert Rice
Ann Hynes
Baird Co
Baxter Wells
Bernstein Institutional
Cassorla Guggenheim
Celeste Mellet
CenterWell Ann
Director Celeste
Division Albert
Division EDT
Division Justin
Division Kevin
Division Lance
Division Mok
Division Scott
Division Windley
EDT day
Fidel Goldman
George Renaudin
Insurance President
Jason Cassorla
LLC Jason
LLC Research
Mellet Chief
Mok Barclays
Officer George
President CenterWell
Relations Rechtin
Renaudin President
Research Division
Scott Fidel
Securities LLC
Wilkes Bernstein
conference Vice
HUM Transcript
Humana Inc. (HUM) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary indicates strong financial performance with a 12% YoY revenue increase, a 15% rise in operating cash flow, and a 10% increase in net income. EPS also grew significantly, supported by share repurchases. The improvement in the Medical Expense Ratio suggests effective cost management. Although there were no operational or strategic updates, the financial metrics alone suggest a positive outlook. Without Q&A insights, the financials remain the primary positive driver.
Humana Inc. (HUM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Humana Inc. (HUM) Q4 2025 Earnings Call Transcript
Unknown2-11
The earnings call reveals a mix of positive and cautious elements. The company shows strong financial performance and operational efficiency, with promising plans for cost savings and strategic acquisitions. However, conservative guidance and lack of share repurchase plans for 2025, combined with unclear management responses in the Q&A, temper enthusiasm. The market reaction is expected to be neutral, considering the balance of positive growth initiatives and cautious financial outlook.
Humana Inc. (HUM) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Neutral11-19
HUM Slides
HUM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
